Clinical trials: Esophagitis
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to determine the safety and efficacy of Rabeprazole extended release (ER) 50 mg versus Esomeprazole 40 mg for healing and symptomatic relief among subjects with erosive gastroesophageal reflux disease…
- Trial name
- NCT00658528
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 88 sites in United States, Argentina and 11 more
- Volunteers
- 1,061 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to investigate the efficacy and safety of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg in subjects with erosive gastroesophageal reflux disease (eGERD).
- Trial name
- NCT00658632
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 85 sites in United States
- Volunteers
- 1,397 people
- Sponsor
- Eisai Inc.
Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study
The purpose of this study is to assess and analyze the safety, tolerability and PK/PD data following single ascending and multiple ascending doses of X842 in healthy subjects.
- Trial name
- NCT03105375
- Testing
- Single ascending dose of X842, Multiple ascending dose of X842, Losec
- Where
- Sweden
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Cinclus Pharma Holding AB
Eosinophilic Esophagitis (EoE)
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab).
- Trial name
- EDESIA (NCT06693531)
- Testing
- dupilumab
- Where
- 54 sites in United States
- Volunteers
- 368 people
- Sponsor
- Regeneron Pharmaceuticals
Eosinophilic Esophagitis
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
This study is designed to investigate the effects of a 12 week course of intravenous QAX576 6mg/kg every 4 weeks in reducing the number of eosinophils in the esophagus of EoE patients by 75% or greater when compared with baseline.
- Trial name
- NCT01022970
- Testing
- QAX576
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Eosinophilic Esophagitis
A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis
This is a randomized, placebo-controlled, double-blind trial to evaluate the efficacy, tolerability, and safety of ESO-101 in adult patients with active eosinophilic esophagitis (EoE).
- Trial name
- NCT04849390
- Testing
- ESO-101
- Where
- 17 sites in Germany, Netherlands and 3 more
- Volunteers
- 43 people
- Sponsor
- EsoCap AG
Eosinophilic Esophagitis (EoE)
Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)
This is a continuation study of Budesonide Oral Suspension (BOS) in adults and adolescents with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-302 extension study.
- Trial name
- NCT03245840
- Testing
- Budesonide oral suspension
- Where
- 45 sites in United States
- Volunteers
- 133 people
- Sponsor
- Shire
Reflux Esophagitis
Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis
The purpose of the study is to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.
- Trial name
- NCT04531475
- Testing
- X842, Lansoprazole
- Where
- 16 sites in China
- Volunteers
- 90 people
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven…
- Trial name
- NCT00251693
- Testing
- Dexlansoprazole MR, Lansoprazole
- Where
- 140 sites in United States, Australia and 13 more
- Volunteers
- 2,038 people
- Sponsor
- Takeda
Erosive Esophagitis
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach.
- Trial name
- NCT02615184
- Testing
- Dexlansoprazole
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 24 people
- Sponsor
- Takeda
Erosive Esophagitis
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically…
- Trial name
- NCT05055128
- Testing
- X842, X842 Dummy, Lansoprazole
- Where
- 42 sites in United States, Bulgaria and 6 more
- Volunteers
- 248 people
- Sponsor
- Cinclus Pharma Holding AB
GERD (Gastroesophageal Reflux Disease)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
The goal of this clinical trial is to investigate how well linaprazan glurate can maintain healed erosive esophagitis (EE) caused by GERD in participants who have participated in a prior healing trial, compared to lansoprazole…
- Trial name
- NCT07313774
- Testing
- Linaprazan glurate - High dose, Linaprazan glurate - Low dose, Lansoprazole - Marketed approved dose
- Sponsor
- Cinclus Pharma Holding AB
Erosive Esophagitis
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed
A study to look at the rates of remission (non re-appearance of erosive esomeprazole) when treated with esomeprazole or lansoprazole; in patients in with erosive esomeprazole (EE) that is in remission (i.e. previously healed EE).
- Trial name
- NCT00644735
- Testing
- Esomeprazole, Lansoprazole
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Gastric Ulcer, Duodenal Ulcer
BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects
The purpose of this study is; To investigate whether a D961H sachet 20 mg is bioequivalent to a D961H HPMC capsule 20 mg by the assessment of percentage of time with intragastric pH>4.
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Esophagitis
- Trial name
- NCT01964131
- Testing
- D961H sachet 20 mg, D961H HPMC capsule 20 mg
- Where
- 2 sites in Japan
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Reflux, Heartburn
Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
The aim of this project is to compare the GERD clinical outcomes in patients where a structured pathway using the GerdQ questionnaire is implemented compared with the clinical outcomes of those treated without this…
- Conditions
- Reflux, Heartburn, Regurgitation, Esophagitis
- Trial name
- NCT00842387
- Where
- 66 sites in Austria, Italy and 3 more
- Volunteers
- 2,370 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire
The purpose of this study is to define the endoscopic findings of minimal change that is significant to clinical significant reflux esophagitis.
- Trial name
- MIGHT (NCT00901004)
- Where
- 7 sites in South Korea
- Volunteers
- 1,550 people
- Sponsor
- AstraZeneca
Erosive Esophagitis(EE), Gastroesophageal Reflux Disease (GERD)
TAK-438 - Safety, Blood Levels & Effects of Repeated Doses
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 in healthy, non-Japanese men male subjects following a randomized, double blind, placebo controlled, sequential panel…
- Trial name
- TAK-438_107 (NCT02141711)
- Testing
- TAK-438
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Takeda
Eosinophilic Esophagitis
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
The primary objectives of the study by study part are: Part A: To determine the treatment effect of dupilumab compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological…
- Trial name
- NCT03633617
- Testing
- Dupilumab
- Where
- 95 sites in United States, Australia and 10 more
- Volunteers
- 321 people
- Sponsor
- Regeneron Pharmaceuticals
Eosinophilic Esophagitis, Celiac Disease
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
This is a single and multiple ascending study to characterize the safety, PK, PD and clinical effect in healthy volunteers and participants with Celiac Disease and Eosinophilic Esophagitis.
- Trial name
- NCT04593251
- Testing
- CALY-002
- Where
- 13 sites in Belgium, Finland and 3 more
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Calypso Biotech BV
Reflux Esophagitis
Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation
The purpose of this study is to exploratorily evaluate the effect of vonoprazan 20 mg on sleep disturbance of patients with reflux esophagitis, who have heartburn and/or regurgitation and ≥ 6.0 in the Pittsburgh Sleep Quality…
- Trial name
- VISTAEXE (NCT03116841)
- Testing
- Vonoprazan
- Where
- 6 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Takeda